Oncobeta GmbH has developed a treatment for Non-Melanoma skin cancer (NMSC) called
Rhenium-SCT. Oncobeta is committed to continually improving patient outcomes and
therefore is sponsoring an international registry.

You are being invited to participate in a registry for patients being treated for non-melanoma skin cancer (NMSC). This study is called a ‘registry’. This means that information will be collected and stored to answer scientific questions about people with the same condition or disease, and who receive treatment for NMSC. You are invited to participate in this Registry because you have undergone or about to undergo treatment for NMSC. This consent form provides you with information to help you make an informed choice. Please read this document carefully and take your time in making your decision. You may find it helpful to discuss it with your friends and family.